How Advanced Therapies Reached the $1 Billion Mark and Attracted Big Deals
Cell and gene therapies have entered the commercial big leagues. In 2025, five treatments – including Johnson & Johnson's Carvykti – crossed the blockbuster threshold with annual sales near or above $1 billion. Carvykti alone generated $1.887 billion, underscoring the market's rapid maturation after years of clinical promise.
That momentum is fueling a fresh wave of dealmaking. In early 2026, Gilead agreed to acquire Arcellx and its CAR-T programme in a transaction valued at up to $7.8 billion. Weeks later, Eli Lilly bought Orna Therapeutics for $2.4 billion, gaining access to a platform for engineering cells inside the body and a CAR-T candidate aimed at B‑cell‑driven autoimmune diseases. Both deals signal a strategic pivot: the next frontier for these therapies lies well beyond oncology, into autoimmune, cardiovascular, neurological and rare disease indications.
The expansion rests on early evidence that CAR‑T cells can induce long-lasting remissions in autoimmune conditions like lupus, myositis and myasthenia gravis by selectively eliminating immune cells responsible for the disease – potentially even reprogramming the entire immune system. If confirmed in larger trials, the paradigm shift could be profound: a single administration might replace a lifetime of chronic immunosuppression.
What the CAR-T Land Grab Means for Pharma, Patients, and Payers
Gilead’s $7.8bn Bet and the CAR‑T Consolidation
The Arcellx deal consolidates Gilead’s position in the CAR‑T space, adding a late‑stage programme to its existing oncology portfolio. The price tag reflects intense competition to lock in next‑generation technologies before clinical data fully mature. With Eli Lilly entering the same arena via Orna, the strategic message is unambiguous: large‑cap pharma sees cell therapy as a pillar of future revenue, not a niche.
Beyond Cancer: Autoimmune Trials Redefine the Market
Clinical observations from lupus and other B‑cell‑mediated diseases have raised a tantalising possibility – “reprogramming” the immune system after a single dose. Emilio Vargas Castrillón, president of the Spanish Society of Clinical Pharmacology, notes that deep, prolonged B‑cell depletion appears to drive sustained remission, challenging the conventional chronic‑treatment model. However, most non‑oncology indications remain in early‑stage development, and translating those results into approved therapies will require consistent manufacture and robust long‑term safety data.
The Manufacturing and Cost‑Effectiveness Puzzle
Historically, the biggest hurdle for advanced therapies has been variability – a living biological product must be manufactured reproducibly at scale. Clinical pharmacologists also stress the need to understand the dose‑exposure‑effect relationship more precisely, and to develop biomarkers that predict which patients will respond. Without those tools, the high upfront cost – often hundreds of thousands of dollars per patient – becomes harder for health systems to justify, even when the treatment delivers a lifetime of benefit.
Executive and Investor Playbook for the Next Wave of Cell and Gene Therapies
- For pharma leaders: Invest in manufacturing platforms that reduce biological variability; the commercial viability of CAR‑T beyond oncology hinges on reproducible, scalable production, as highlighted by clinical pharmacologists.
- For investors: Monitor autoimmune trial readouts from Arcellx and other CAR‑T developers closely – early remission data in lupus and myasthenia gravis could signal which platform has true disease‑modifying potential.
- For health system payers: Begin modelling cost‑effectiveness frameworks that account for the one‑and‑done nature of these therapies, factoring in avoided costs of long‑term chronic care to justify the high initial price tag.
- For regulators and clinical pharmacologists: Prioritise the development of predictive biomarkers and standardised potency assays to strengthen the evidence base for patient selection and to support consistent manufacturing oversight.
Risk & Opportunity Assessment
| Commercial Risk | Medium | High upfront costs and uncertain reimbursement frameworks could slow adoption even of blockbuster‑status therapies, particularly in stretched public health systems. |
| Competitive Risk | High | Multiple well‑capitalised companies – J&J, Gilead, Eli Lilly and others – are racing to acquire CAR‑T platforms and expand into non‑oncology indications, compressing the window for differentiation. |
| Regulatory Risk | Medium | Expanding labels into autoimmune diseases will demand robust long‑term safety data and consistent manufacturing, though no acute regulatory barrier has emerged yet. |
| Reputation Risk | Low | Safety profiles have been manageable and no major scandal has shaken confidence; the primary concern is efficacy in new indications, not public distrust. |
| Technology Disruption | High | A single‑dose CAR‑T that induces lasting remission in autoimmune diseases would displace chronic immunosuppressive regimens, fundamentally altering treatment paradigms. |
| Commercial Opportunity | High | Moving beyond oncology opens addressable markets in cardiology, neurology and rare diseases worth tens of billions of dollars, underpinning the M&A surge. |
Comments 0